Reactivity: human, mouse, rat
Articlecode: 14-6746-81
Contents: Affinity Purified anti-mouse/human/rat Neu polyclonal
Catalog Number: 14-6746
Sizes: 10 ug, 50 ug
Formulation: 200 µg/ml of rabbit polyclonal IgG in PBS containing 0.1 % sodium azide and 0.2% gelatin.
Storage Conditions: Store at 4°C.
DO NOT FREEZE.
Clone: Polyclonal
Isotype: Rabbit IgG
|
|
|
Available Formats of This Product
|
Cat. No.
|
Format
|
Excite
(nm)
|
Emit
(nm)
|
Reported Applications
|
14-6746
|
|
N/A
|
N/A
|
|
Description
The polyclonal antibody reacts with mouse, rat, and human Neu; the antibody was raised against a peptide mapping to the carboxy terminus of human Neu (HER2 or ErbB-2). The Neu/HER-2 (also known as EGFR-2 or ErbB-2) is a transmembrane tyrosine kinase receptor and a well-defined tumor antigen. Neu/HER-2 is a shared antigen among multiple tumor types. Patients with HER-2/neu protein-overexpressing breast, ovarian, non-small cell lung, colon, and prostate cancers have been shown to have a pre-existent immune response to Neu/HER-2 (1,2). Neu/HER-2 amplification/overexpression confers more aggressive and malignant characteristics on breast cancer cells. Patients with Neu/HER-2-amplified breast cancer have a worse prognosis than those with normal Neu/HER-2 expression (3).
Usage
For research use only, not for diagnostic or therapeutic use. Purified anti-mo/hu/rat Neu poly has been reported for use in immunoprecipitation, immunoblotting (WB), and immunohistochemical staining.
Applications Tested
Purified anti-mo/hu/rat Neu poly has been tested by immunoblotting (WB). (1:200 starting dilution). It is recommended that this antibody be titrated for optimal performance in the assay of interest.
Related Products
Cat. 66-P746 Blocking Peptides for anti-mouse/human/rat Neu polyclonal
References
1. Bernhard H, Salazar L, Schiffman K, Smorlesi A, Schmidt B, Knutson KL, Disis ML. Vaccination against the HER-2/neu oncogenic protein. Int J Endocr Relat Cancer 2002 Mar;9(1):33-44.
2. Lohrisch C, Piccart M. HER2/neu as a predictive factor in breast cancer. Clin Breast Cancer 2001 Jul;2(2):129-35; discussion 136-7.
3. Hortobagyi GN. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol 2001 Dec;28(6 Suppl 18):43-7
|
